Evidence map›Paper›PMID 25767376›Full record

ArticleDrug design, development and therapy2015

Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.

Chun-Xiu Yuan, Zhi-Wei Zhou, Yin-Xue Yang, Zhi-Xu He, Xueji Zhang, Dong Wang, Tianxing Yang, Si-Yuan Pan, Xiao-Wu Chen, Shu-Feng Zhou

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Oncogenic and immunological roles of LAMP5 across cancers and its potential utility in bladder cancer.Apoptosis : an international journal on programmed cell death · 2026
    Article
  3. Targetable pathways for drug repurposing in gastric cancer.World journal of gastroenterology · 2025
    Review
  4. Review
  5. Article
  6. Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer.International journal of molecular sciences · 2024
    Review
  7. The Supression of Migration and Metastasis via Inhibition of Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma Cells Applied Danusertib.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024
    Article
  8. Repurposed Drugs in Gastric Cancer.Molecules (Basel, Switzerland) · 2022
    Review
  9. Article
  10. Review
  11. Article
  12. C1222C Deletion in Exon 8 ofFrontiers in oncology · 2020
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. miR-340 Inhibits Proliferation and Induces Apoptosis in Gastric Cancer Cell Line SGC-7901, Possibly via the AKT Pathway.Medical science monitor : international medical journal of experimental and clinical research · 2017
    Article
  20. A protein and mRNA expression-based classification of gastric cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Chun-Xiu YuanDepartment of Oncology, General Hospital, Ningxia Medical University, Yinchuan, People's Republic of China ; Department of Pharmaceutical Science, College of Pharmacy, University of South Florida, Tampa, FL, USA.
Zhi-Wei ZhouDepartment of Pharmaceutical Science, College of Pharmacy, University of South Florida, Tampa, FL, USA ; Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center and Sino-US Joint Laboratory for Medical Sciences, Guiyang Medical University, Guiyang, People's Republic of China.
Yin-Xue YangDepartment of Colorectal Surgery, General Hospital, Ningxia Medical University, Yinchuan, People's Republic of China.
Zhi-Xu HeGuizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center and Sino-US Joint Laboratory for Medical Sciences, Guiyang Medical University, Guiyang, People's Republic of China.
Xueji ZhangResearch Center for Bioengineering and Sensing Technology, University of Science and Technology Beijing, People's Republic of China.
Dong WangCancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing, People's Republic of China.
Tianxing YangDepartment of Internal Medicine, University of Utah and Salt Lake Veterans Affairs Medical Center, Salt Lake City, UT, USA.
Si-Yuan PanDepartment of Pharmacology, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
Xiao-Wu ChenDepartment of General Surgery, The First People's Hospital of Shunde, Southern Medical University, Shunde, People's Republic of China.
Shu-Feng ZhouDepartment of Pharmaceutical Science, College of Pharmacy, University of South Florida, Tampa, FL, USA.
Guiyang Medical University · CNUniversity of South Florida · USUniversity of Utah · USBeijing University of Chinese Medicine · CNNingxia Medical University · CNThe First People's Hospital of Shunde · CNUniversity of Science and Technology Beijing · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer is the second leading cause of cancer-related death worldwide, with a poor response to current chemotherapy. Danusertib is a pan-inhibitor of the Aurora kinases and a third-generation Bcr-Abl tyrosine kinase inhibitor with potent anticancer effects, but its antitumor effect and underlying mechanisms in the treatment of human gastric cancer are unknown. This study aimed to investigate the effects of danusertib on cell growth, apoptosis, autophagy, and epithelial to mesenchymal transition and the molecular mechanisms involved in human gastric cancer AGS and NCI-N78 cells. The results showed that danusertib had potent growth-inhibitory, apoptosis-inducing, and autophagy-inducing effects on AGS and NCI-N78 cells. Danusertib arrested AGS and NCI-N78 cells in G2/M phase, with downregulation of expression of cyclin B1 and cyclin-dependent kinase 1 and upregulation of expression of p21 Waf1/Cip1, p27 Kip1, and p53. Danusertib induced mitochondria-mediated apoptosis, with an increase in expression of proapoptotic protein and a decrease in antiapoptotic proteins in both cell lines. Danusertib induced release of cytochrome c from the mitochondria to the cytosol and triggered activation of caspase 9 and caspase 3 in AGS and NCI-N78 cells. Further, danusertib induced autophagy, with an increase in expression of beclin 1 and conversion of microtubule-associated protein 1A/1B-light chain 3 (LC3-I) to LC3-II in both cell lines. Inhibition of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) and p38 mitogen-activated protein kinase pathways as well as activation of 5' AMP-activated protein kinase contributed to the proautophagic effect of danusertib in AGS and NCI-N78 cells. SB202191 and wortmannin enhanced the autophagy-inducing effect of danusertib in AGS and NCI-N78 cells. In addition, danusertib inhibited epithelial to mesenchymal transition with an increase in expression of E-cadherin and a decrease in expression of N-cadherin in both cell lines. Taken together, danusertib has potent inducing effects on cell cycle arrest, apoptosis, and autophagy, but has an inhibitory effect on epithelial to mesenchymal transition, with involvement of signaling pathways mediated by PI3K/Akt/mTOR, p38 mitogen-activated protein kinase, and 5' AMP-activated protein kinase in AGS and NCI-N78 cells.

Indexed as

Antineoplastic AgentsApoptosisAurora KinasesBenzamidesCell Cycle CheckpointsCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorEpithelial-Mesenchymal TransitionHumansMolecular StructurePhosphatidylinositol 3-KinaseProtein Kinase InhibitorsProto-Oncogene Proteins c-ablProto-Oncogene Proteins c-aktPyrazolesAntineoplastic AgentsAurora KinasesBenzamidesdanusertibPhosphatidylinositol 3-KinaseProtein Kinase InhibitorsProto-Oncogene Proteins c-ablProto-Oncogene Proteins c-aktPyrazolesTOR Serine-Threonine KinasesapoptosisAurora kinaseautophagydanusertibepithelial to mesenchymal transitiongastric cancer

Identifiers

PMID25767376
PMCPMC4354435
OpenAlexW2120775131

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.